DUBLIN, March 12, 2024 /PRNewswire/ -- Jazz
Pharmaceuticals plc (Nasdaq: JAZZ) will host a virtual R&D Day,
Tuesday, March 19, from 8:00 a.m. to 10:00 a.m. ET, focused on
zanidatamab, a differentiated, bispecific antibody in late-stage
development with the potential to transform the standard of care in
multiple HER2-positive cancers. The webcast will highlight the
mechanistic rationale and clinical data that support further
development of zanidatamab as a treatment for biliary tract cancer
(BTC), gastroesophageal adenocarcinoma (GEA) and breast cancer.
External key opinion leaders in GEA and breast cancer will also
discuss current treatment paradigms and unmet needs for those
cancers, and how zanidatamab may provide a new treatment option for
patients.
Audio webcast/conference call:
U.S. Dial-In Number: +1
888 596 4144
Additional international dial-in numbers are available here.
Conference ID: 8217388
Interested parties may register for the zanidatamab R&D Day
webcast via the Investors section of the Jazz Pharmaceuticals
website at
https://investor.jazzpharma.com/investors/events-presentations. To
ensure a timely connection, it is recommended that participants
register at least 15 minutes prior to the scheduled webcast.
A replay of the webcast will be available via the Investors
section of the Jazz Pharmaceuticals website at
https://investor.jazzpharma.com/investors/events-presentations.
About Jazz Pharmaceuticals
Jazz
Pharmaceuticals plc (Nasdaq: JAZZ) is a global
biopharmaceutical company whose purpose is to innovate to transform
the lives of patients and their families. We are dedicated to
developing life-changing medicines for people with serious diseases
— often with limited or no therapeutic options. We have a diverse
portfolio of marketed medicines, including leading therapies for
sleep disorders and epilepsy, and a growing portfolio of cancer
treatments. Our patient-focused and science-driven approach powers
pioneering research and development advancements across our robust
pipeline of innovative therapeutics in oncology and neuroscience.
Jazz is headquartered in Dublin,
Ireland with research and development laboratories,
manufacturing facilities and employees in multiple countries
committed to serving patients worldwide. Please visit
www.jazzpharmaceuticals.com for more information.
Contacts:
Jazz Investor Contact:
Andrea
N. Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717
Jazz Media Contact:
Kristin
Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948
Logo -
https://mma.prnewswire.com/media/272253/4588297/Jazz_Pharmaceuticals_New_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/jazz-pharmaceuticals-to-host-virtual-zanidatamab-rd-day-on-tuesday-march-19-2024-302087134.html